Physician profile
Guy F Webster
NPI 1831281138
$52,331.00
in general payments reported to CMS, 2019-2025
27 companies · $1,650 in 2025
The $1,650 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21K · 2020: $14K · 2021: $8,301 · 2022: $1,071 · 2023: $4,002 · 2024: $1,477 · 2025: $1,650.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,720 · Consulting Fee: $2,250 · Education: $160.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,719.65 |
| Consulting Fee | $2,250.00 |
| Education | $159.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma International Sas | $16,350.99 | 2019 | |
| Vyne Pharmaceuticals INC. | $14,222.02 | 2020-2021 | |
| Galderma Laboratories, L.P. | $10,636.21 | 2019-2024 | Aklief |
| Arcutis Biotherapeutics, INC. | $2,552.78 | 2023-2025 | Zoryve |
| Janssen Biotech, INC. | $1,331.41 | 2019-2025 | Tremfya, Simponi, Stelara |
| Abbvie INC. | $1,065.91 | 2019-2025 | Skyrizi, Rinvoq |
| Almirall LLC | $995.67 | 2019-2025 | Klisyri |
| Lilly USA, LLC | $724.72 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Incyte Corporation | $611.72 | 2021-2025 | Opzelura |
| Sun Pharmaceutical Industries INC. | $587.50 | 2019-2025 | Ilumya, Absorica Ld, Winlevi |
| Pfizer INC. | $510.71 | 2019-2025 | |
| Ucb, INC. | $407.62 | 2021-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $357.98 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $337.62 | 2019-2025 | Dupixent, Libtayo |
| Leo Pharma INC. | $305.09 | 2021-2025 | Adbry, Anzupgo |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $299.12 | 2019-2025 | Arazlo, Cabtreo, Siliq |
| Amgen INC. | $236.74 | 2021-2025 | Otezla, Otezla |
| Genzyme Corporation | $220.18 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $138.27 | 2022-2025 | Spevigo |
| Sanofi-Aventis U.S. LLC | $72.00 | 2021 | |
| Dermira, INC. | $69.40 | 2019-2021 | |
| Organon LLC | $65.05 | 2025 | Vtama |
| Genentech USA, INC. | $63.45 | 2023-2024 | Erivedge |
| Encore Dermatology INC. | $57.73 | 2020 | |
| Journey Medical Corporation | $42.44 | 2022-2023 | |
| Dermavant Sciences, INC. | $38.20 | 2023 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $30.47 | 2024-2025 | Sotyktu |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Guy Webster listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.